How should managed care treat onychomycosis?

American Journal of Managed Care

Volumn 4, Issue 10, 1998, Pages 1471-1481

  Katz, H Irving ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Dermatology Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTACID AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN; DIDANOSINE; DIGOXIN; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; ORAL ANTIDIABETIC AGENT; PHENOBARBITAL; PHENYTOIN; QUINIDINE; SIMVASTATIN; TACROLIMUS; TERBINAFINE; TRIAZOLAM; TUBERCULOSTATIC AGENT; WARFARIN;

CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DRUG CHOICE; DRUG POTENCY; DRUG SAFETY; EMBRYOTOXICITY; GASTROINTESTINAL TOXICITY; HEALTH MAINTENANCE ORGANIZATION; HUMAN; NOTE; ONYCHOMYCOSIS; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DISEASE MANAGEMENT; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; EDUCATION, MEDICAL, CONTINUING; HUMANS; MANAGED CARE PROGRAMS; ONYCHOMYCOSIS; PATIENT SELECTION; QUALITY OF LIFE; UNITED STATES;

EID: 0031765169     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (62)

1. Zaias N. Clinical manifestations of onychomycosis. Clin Exp Dermatol 1992;17(suppl 1):6-7.
2. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-143.
3. Korting HC, Schafer-Korting M. Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol 1992;128:243-248.
4. Pierard GE, Arrese-Estrada J, Pierard-Franchimont C. Treatment of onychomycosis: Traditional approaches. J Am Acad Dermatol 1993;29:S41-S45.
5. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994;31:578-581.
6. Rosen T. New approaches to the diagnosis and management of onychomycosis. International Symposium, Monaco, April 1-2, 1993. Int J Dermatol 1994;33:292-299.
7. Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group. Br J Dermatol 1994;130 (suppl 43):35-44.
8. Bergman W, Rutten FF. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine]. Ned Tijdschr Geneeskd 1994;138:2346-2350.
9. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994;130(suppl 43): 32-34.
10. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey. Br J Dermatol 1992;126(suppl 39):23-27.
11. Wenig JA. The systemic treatment of onychomycosis. Clin Podiatr Med Surg 1995;12:263-274.
12. Chren MM. Costs of therapy for dermatophyte infections [see comments]. J Am Acad Dermatol 1994;31:S103-S106.
13. Elewski BE, Hay RJ. Cost of therapy for dermatophyte infections. Letter. J Am Acad Dermatol 1995;32:1062.
14. Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails? Arch Dermatol 1995;131:937-942.
15. Midgley G, Moore MK, Cook JC, Phan QG. Mycology of nail disorders. J Am Acad Dermatol 1994;31:S68-S74.
16. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res 1993;2:341-348.
17. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994;130(suppl 43):15.
18. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Onychomycosis. J Am Acad Dermatol 1996;34:116-121.
19. Pariser DM. Superficial fungal infections. A practical guide for primary care physicians. Postgrad Med 1990; 87:205-214.
20. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992;17(suppl 1):37-40.
21. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240-259.
22. Suarez SM, Silvers DN, Scher RK, Pearlstein HH, Auerbach R. Histologic evaluation of nail clippings for diagnosing onychomycosis [see comments]. Arch Dermatol 1991;127:1517-1519.
23. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991;19:433-445.
24. Effendy I, Kolczak H, Ossowski B, Hohler T. [Topical therapy of onychomycoses with 8% ciclopirox laquer. An open, non-comparative study]. Fortschr Med 1993;111: 205-208.
25. Roberts P. Caution with topical anaesthesia - TAC. Med J Anst 1994;160:730-731. Letter.
26. Sporanox (itraconazole capsules). Package insert. Titusville, NJ: Janssen Pharmaceutica; 1997.
27. Lamisil (terbinafine hydrochloride tablets) Tablets. Package insert. East Hanover, NJ: Sandoz Pharmaceuticals Corporation; 1996.
28. Meinhof W. Kinetics and spectrum of activity of oral antifungals: The therapeutic implications. J Am Acad Dermatol 1993;29:S37-S41.
29. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993;29:S45-S50.
30. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail: New implications for treatment in onychomycosis. J Am Acad Dermatol 1992;26:731-735.
31. Breckenridge A. Clinical significance of interactions with antifungal agents. Review. Br J Dermatol 1992;126(suppl 39):19-22.
32. Honig PK, Worham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993;53:630-636.
33. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use [see comments]. JAMA 1990;264:2788-2790.
34. Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992;30: 451-460.
35. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43: 259-284.
36. Cribier B, Grosshans E. Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses. Ann Dermatol Venereol 1994;121:15-20.
37. Seyffer R, Eichelbaum M, Jensen JC, Klotz U. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol 1989;37:231-233.
38. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: Results of a postmarketing study in 25,884 patients. Arch Dermatol 1997;133:1213-1219.
39. van der Kuy P-HM, Hooymans PM. Nortriptyline intoxication by terbinafine. Br Med J 1998;316:441.
40. Warwick JA, Corrall RJ. Serious interaction between warfarin and oral terbinafine. Br Med J 1998;316:440.
41. Bräutigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. Br Med J 1995;311:919-922.
42. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe mycosis; terbinafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 1996;134(suppl 46):16-17.
43. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism. Mycoses 1993;36:421-424.
44. Moreno F, Hardin TC, Rinaldi MG, Graybill JR. Itraconazole-didanosine excipient interaction. JAMA 1993;269:1508. Letter.
45. Blomley M, Teare EL, de Beider A, Thway Y, Weston M. Itraconazole and anti-tuberculosis drugs. Lancet 1990;336: 1255. Letter.
46. Hismanal (astemizole) Tablets. Prescribing information. In: Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996:1293-1295.
47. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals. Prevention and management. Drug Saf 1992;7:323-363.
48. Brodell RT, Elewski BE. Clinical pearl: Systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995;33:259-260.
49. Propulsid (cisapride) Tablets. Prescribing information. In: Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996:1300-1301.
50. Sandimmune (cyclosporine capsules USP). Prescribing information. In: Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996: 2286-2290.
51. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-329.
52. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994; 14:509-513.
53. Alderman CP, Jersmann HP. Digoxin-itraconazole interaction. Med J Aust 1993;159:838-839. Letter.
54. Kauffman CA, Bagnasco FA. Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992;15:886-887. Letter.
55. Baciewicz AM, Baciewicz FA, Jr. Ketoconazole and fluconazole drug interactions. Arch Intern Med 1993;153: 1970-1976.
56. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-485.
57. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994;18:266. Letter.
58. Zocor (simvastatin) Tablets. Prescribing information. In: Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996:1775-1779.
59. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-193.
60. Seldane (terfenadine). Prescribing information. In: Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996:1536-1538.
61. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics, ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-607.
62. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. Br Med J 1990; 301:669.